The Journal of Practical Medicine >

2025 , Vol. 41 >Issue 14: 2152 - 2159

DOI: https://doi.org/10.3969/j.issn.1006-5725.2025.14.005

Feature Reports：Breast carcinoma

Clinical value analysis of different MRI measurement methods in evaluating the efficacy of neoadjuvant therapy for breast cancer

  • Yuling DUAN ,
  • Xuezhi ZHOU ,
  • Yongyi LI ,
  • Lixia MA ,
  • Desheng YANG ,
  • Jiao CHENG ,
  • Yan WU ,
  • Tao LIU ,
  • Guoyuan JIANG ,
  • Mei. WANG
Expand
  • Department of Breast and Thyroid Surgery，the Third Affiliated Hospital of Zunyi Medical University （Zunyi City First People's Hospital），Zunyi 563000，Guizhou，China

Received date: 2025-03-20

  Online published: 2025-07-29

Fold

Abstract

Objective To compare the diagnostic performance of three breast MRI measurement methods—RECIST 1.1， the optimal method， and three-dimensional （3D） volumetric assessment—in assessing the efficacy of neoadjuvant chemotherapy （NAC） in breast cancer patients， with the objective of identifying the most clinically practical approach. Methods A total of 110 breast cancer patients who underwent NAC followed by surgical treatment between 2019 and 2023 were included in the study. Breast magnetic resonance imaging （MRI） was conducted within one week before and after the completion of NAC. Tumor response was evaluated using RECIST 1.1 criteria， widely recognized as the optimal method， as well as 3D volume measurement. Pathological response was determined according to the Miller-Payne grading system. Sensitivity， specificity， accuracy， and the area under the receiver operating characteristic curve （AUC） were computed and compared using the DeLong test. Results The AUC values for RECIST 1.1， the optimal method， and 3D volumetric assessment were 0.768， 0.795， and 0.883， respectively. The 3D volumetric assessment exhibited significantly better discriminative performance （P < 0.05）， with the highest sensitivity （98.9%）， specificity （77.8%）， and accuracy （95.5%）. Additionally， the optimal method demonstrated superior performance over RECIST 1.1 across multiple parameters. Conclusions 3D volumetric measurement demonstrates superior performance compared to RECIST 1.1 and the optimal method in evaluating the response to NAC， offering a more accurate and comprehensive assessment tool. Additionally， the optimal method shows advantages over RECIST 1.1 and may serve as a practical alternative in settings where 3D software is not available.

Key words： breast cancer; magnetic resonance imaging; neoadjuvant chemotherapy; 3D volume measurement; efficacy evaluation; ROC curve

Cite this article

Yuling DUAN , Xuezhi ZHOU , Yongyi LI , Lixia MA , Desheng YANG , Jiao CHENG , Yan WU , Tao LIU , Guoyuan JIANG , Mei. WANG . Clinical value analysis of different MRI measurement methods in evaluating the efficacy of neoadjuvant therapy for breast cancer[J]. The Journal of Practical Medicine, 2025 , 41(14) : 2152 -2159 . DOI: 10.3969/j.issn.1006-5725.2025.14.005

References

[1] 中国抗癌协会乳腺癌专业委员会，中华医学会肿瘤学分会乳腺肿瘤学组. 中国抗癌协会乳腺癌诊治指南与规范（2024年版）［J］. 中国癌症杂志， 2023，33（12）：1092-1187.
[2] 刘芬，赵辉，郭利敏. 多组学联合检测对乳腺癌临床病理特征、新辅助化疗效果的评估效能［J］. 实用医学杂志，2024，40（24）：3539-3546.
[3] 邵志敏，吴炅，江泽飞，等. 中国乳腺癌新辅助治疗专家共识（2022年版） ［J］. 中国癌症杂志，2022， 32 （1）： 80-89.
[4] 肖晶晶，黄美玲，延常姣，等. Her-2阳性乳腺癌新辅助化疗联合靶向治疗获得病理完全缓解的影响因素［J］. 实用医学杂志，2022，38（5）：542-546.
[5] THERESE B B， BETHANY L N， JENNIFER L B， et al. NCCN Guidelines? Insights： Breast Cancer Screening and Diagnosis， Version 1.2023 ［J］. J Natl Compr Canc Netw，2023，21（9）：900-909.
[6] LU N， DONG J， FANG X， et al. Predicting pathologic response to neoadjuvant chemotherapy in patients with locally advanced breast cancer using multiparametric MRI ［J］. BMC Med Imaging，2021，21（1）：1-13. doi:10.1186/s12880-021-00688-z
[7] LIANG X， CHEN X， YANG Z， et al. Early prediction of pathological complete response to neoadjuvant chemotherapy combining DCE-MRI and apparent diffusion coefficient values in breast Cancer ［J］. BMC Cancer， 2022， 22（1）：1250. doi:10.1186/s12885-022-10315-x
[8] WANG X， HUA H， HAN J， et al. Evaluation of Multiparametric MRI Radiomics-Based Nomogram in Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer： A Two-Center study ［J］. Clin Breast Cancer，2023，23（6）：e331-e344. doi:10.1016/j.clbc.2023.05.010
[9] SUDHIR R， KOPPULA V C， RAO T S， et al. Accuracy of digital mammography， ultrasound and MRI in predicting the pathological complete response and residual tumor size of breast cancer after completion of neoadjuvant chemotherapy ［J］. Indian J Cancer，2022，59（3）：345-353. doi:10.4103/ijc.ijc_795_19
[10] MIN K， TONG L， TANG L， et al. Head-to-head comparison of contrast-enhanced mammography and contrast-enhanced MRI for assessing pathological complete response to neoadjuvant therapy in patients with breast cancer： A meta-analysis ［J］. Cancer Treat Res Commun，2023，202（1）：1-9. doi:10.1007/s10549-023-07034-7
[11] PENG Y， YUAN F， XIE F， et al. Comparison of automated breast volume scanning with conventional ultrasonography， mammography， and MRI to assess residual breast cancer after neoadjuvant therapy by molecular type ［J］. Clin Radiol， 2023，78（5）：e393-e400. doi:10.1016/j.crad.2022.12.002
[12] KO C C， YEH L R， KUO Y T， et al. Imaging biomarkers for evaluating tumor response： RECIST and beyond. ［J］. Biomark Res，2021，9（1）：52. doi:10.1186/s40364-021-00306-8
[13] LITIèRE S， BOGAERTS J. Imaging endpoints for clinical trial use： A RECIST perspective ［J］. J Immunother Cancer，2022，10（11）：e005092. doi:10.1136/jitc-2022-005092
[14] GAURAV JYOTI B， AMARTA J， GENIE K C W， et al. Diagnostic accuracy of magnetic resonance imaging to evaluate axillary lymph node status in breast cancer patients receiving neoadjuvant chemotherapy［J］.Br J Radiol，2023，96（1143）：20220904. doi:10.1259/bjr.20220904
[15] KWON M R， CHU J， KOOK S H， et al. Factors associated with radiologic-pathologic discordance in magnetic resonance imaging after neoadjuvant chemotherapy for breast cancer ［J］. Clin Imaging，2022，89：1-9. doi:10.1016/j.clinimag.2022.05.002
[16] KIM Y， SIM S H， PARK B， et al. Criteria for identifying residual tumours after neoadjuvant chemotherapy of breast cancers： A magnetic resonance imaging study ［J］. Sci Rep， 2021，11（1）：634. doi:10.1038/s41598-020-79743-8
[17] CHANG Y C， HUANG C S， LIU Y J， et al. Angiogenic response of locally advanced breast cancer to neoadjuvant chemotherapy evaluated with parametric histogram from dynamic contrast-enhanced MRI ［J］. Phys Med Biol，2004，49（16）：3593-3602. doi:10.1088/0031-9155/49/16/007
[18] SHARMA U， DANISHAD K K， SEENU V， et al. Longitudinal study of the assessment by MRI and diffusion-weighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy ［J］. NMR Biomed，2009，22（1）：104-113. doi:10.1002/nbm.1245
[19] RAM S. One Size Fits All？-Not Anymore： Personalizing Breast Cancer Treatment with Use of a Semiautomated Functional Tumor Volume-based Predictive Model in the Assessment of Neoadjuvant Therapy Response ［J］. Radiol Imaging Cancer，2023，5（4）：e230089. doi:10.1148/rycan.230089
[20] ONISHI N， BARENG T J， GIBBS J， et al. Effect of Longitudinal Variation in Tumor Volume Estimation for MRI-guided Personalization of Breast Cancer Neoadjuvant Treatment ［J］. Radiol Imaging Cancer，2023，5（4）：e220126.
[21] PANTHI B， ADRADA B E， CANDELARIA R P， et al. Assessment of Response to Neoadjuvant Systemic Treatment in Triple-Negative Breast Cancer Using Functional Tumor Volumes from Longitudinal Dynamic Contrast-Enhanced MRI ［J］. Cancers （Basel），2023，15（4）：1025. doi:10.3390/cancers15041025
[22] SCHWARTZ L H， LITIèRE S， DE VRIES E， et al. RECIST 1.1-Update and clarification： From the RECIST committee ［J］. Eur J Cancer，2016，62：132-137. doi:10.1016/j.ejca.2016.03.081
[23] BRUIX J， SHERMAN M， LLOVET J M， et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver ［J］. J Hepatol，2001，35（3）：421-430. doi:10.1016/s0168-8278(01)00130-1
[24] BONEKAMP S， HALAPPA V G， GESCHWIND J F， et al. Unresectable hepatocellular carcinoma： MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy ［J］. Radiology， 2013，268（2）：431-439. doi:10.1148/radiol.13122307
[25] CHAPIRO J， LIN M， DURAN R， et al. Assessing tumor response after loco-regional liver cancer therapies： The role of 3D MRI ［J］. Expert Rev Anticancer Ther，2015，15（2）：199-205. doi:10.1586/14737140.2015.978861
[26] ZABOROWSKI A M， WONG S M. Neoadjuvant systemic therapy for breast cancer ［J］. Br J Surg，2023，110（7）：765-772. doi:10.1093/bjs/znad103
[27] TAMIRISA N， HUNT K K. Neoadjuvant Chemotherapy， Endocrine Therapy， and Targeted Therapy for Breast Cancer： ASCO Guideline ［J］. Ann Surg Oncol，2022，29（3）：1489-1492. doi:10.1245/s10434-021-11223-3
[28] VAN LA PARRA R F D， CLOUGH K B， THYGESEN H H， et al. Oncological Safety of Oncoplastic Level Ⅱ Mammoplasties After Neoadjuvant Chemotherapy for Large Breast Cancers： A Matched-Cohort Analysis ［J］. Ann Surg Oncol， 2021，28（11）：5920-5928. doi:10.1245/s10434-021-09829-8
[29] IANNESSI A， BEAUMONT H， LIU Y， et al. RECIST 1.1 and lesion selection： How to deal with ambiguity at baseline？ ［J］. Insights Imaging，2021，12（1）：36. doi:10.1186/s13244-021-00976-w
[30] BEAUMONT H， IANNESSI A. Can we predict discordant RECIST 1.1 evaluations in double read clinical trials？ ［J］. Front Oncol， 2023，13：1239570. doi:10.3389/fonc.2023.1239570
[31] YIN X， HADJILOUCAS S， ZHANG Y， et al. MRI radiogenomics for intelligent diagnosis of breast tumors and accurate prediction of neoadjuvant chemotherapy responses-a review ［J］. Comput Methods Programs Biomed，2022，214： 106510. doi:10.1016/j.cmpb.2021.106510
[32] LIANG X， CHEN X， YANG Z， et al. Early prediction of pathological complete response to neoadjuvant chemotherapy combining DCE-MRI and apparent diffusion coefficient values in breast Cancer ［J］. BMC Cancer，2022，22（1）：1250. doi:10.1186/s12885-022-10315-x
[33] CHANG Y， HUANG C， LIU Y， et al. Angiogenic response of locally advanced breast cancer to neoadjuvant chemotherapy evaluated with parametric histogram from dynamic contrast-enhanced MRI ［J］. Phys Med Biol，2004，49（16）：3593-3602. doi:10.1088/0031-9155/49/16/007
[34] SHARMA U， DANISHAD K， SEENU V， et al. Longitudinal study of the assessment by MRI and diffusion-weighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy ［J］. NMR Biomed，2009，22（1）：104-113. doi:10.1002/nbm.1245
[35] DESMAISON C， NICCOLI P， OZIEL TAIEB S， et al. Transarterial chemoembolization （TACE） for neuroendocrine liver metastasis （NELM）： Predictive value of volumetric arterial enhancement （VAE） on baseline MRI ［J］. Bull Cancer， 2023，110（3）：308-319. doi:10.1016/j.bulcan.2022.12.007
[36] RAHIMPOUR M， SAINT MARTIN M， FROUIN F， et al. Visual ensemble selection of deep convolutional neural networks for 3D segmentation of breast tumors on dynamic contrast enhanced MRI ［J］. Eur Radiol，2023，33（2）：959-969. doi:10.1007/s00330-022-09113-7
[37] PARK G， KIM S， NAM Y， et al. 3D Breast Cancer Segmentation in DCE-MRI Using Deep Learning With Weak Annotation ［J］. J Magn Reson Imaging，2024，59（6）：2252-2262. doi:10.1002/jmri.28960
[38] WANG L， LUO R， CHEN Y， et al. Breast Cancer Growth on Serial MRI： Volume Doubling Time Based on 3-Dimensional Tumor Volume Assessment ［J］. J Magn Reson Imaging，2023，58（4）：1303-1313. doi:10.1002/jmri.28670
[39] MARTINCICH L， MONTEMURRO F， DE ROSA G， et al. Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging ［J］. Breast Cancer Res Treat，2004，83（1）：67-76. doi:10.1023/b:brea.0000010700.11092.f4
[40] HYLTON N， GATSONIS C， ROSEN M， et al. Neoadjuvant Chemotherapy for Breast Cancer： Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL ［J］. Radiology，2016，279（1）：44-55. doi:10.1148/radiol.2015150013
[41] GRADISHAR W， MORAN M， ABRAHAM J， et al. Breast Cancer， Version 3.2022， NCCN Clinical Practice Guidelines in Oncology ［J］. J Natl Compr Canc Netw，2022，20（6）： 691-722.
[42] LOIBL S， ANDRé F， BACHELOT T， et al. Early breast cancer： ESMO Clinical Practice Guideline for diagnosis， treatment and follow-up ［J］. Ann Oncol，2024，35（2）：159-182. doi:10.1016/j.annonc.2023.11.016
Options
Outlines

/

〈 〉